Select Country

 
877-783-6728 (877-StemSave)

StemSave Blog

Big Pharma Wades into Regenerative Medicine

Posted by maxi@stemsave.com on Dec 15, 2016 4:00:00 PM

Bayer-symbol.jpg

A $225m investment from pharmaceutical giant Bayer catapults BlueRock Therapeutics onto the stem cell therapy stage. BlueRock will initially focus on cardiovascular and neurological treatments.  A team led by Dr. Michael Laflamme and Dr. Gordon Keller will concentrate on regenerating heart muscle for patients who have suffered a heart attack, whilst a team led by Dr. Lorenz Studer and Dr. Viviane Tabar will concentrate on restoring dopamine-producing cells in patients with Parkinson's disease .

"We have closely tracked the field of regenerative medicine for the past five years and believe the time is right to invest in stem cell therapies given recent breakthroughs in cell differentiation, manufacturing and engineering," commented Dr. Jerel Davis, managing director at Versant Ventures.

As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.

 

The Future of Regenerative Medicine is Now™

To view the full article, click here.

Topics: parkinsons disease, Heart Attack, stem cell therapy, Bayer, BlueRock Therapeutics, cardiovascular treatments, neurological treatments

AAOMS

AAOMS - American Association of Oral and Maxillofacial Surgeons

 

As the industry leader, StemSave is the only stem cell banking service to be designated as an ASI approved program.

Subscribe to Email Updates

Join our Newsletter

Recent Posts

Posts by Topic

see all